Ranibizumab

證據等級: L5

預測適應症: 10 個

Ranibizumab: From Diabetic Macular Edema to Severe Nonproliferative Diabetic Retinopathy

One-Sentence Summary

Ranibizumab is an anti-VEGF (vascular endothelial growth factor) antibody fragment, with established use in neovascular eye diseases such as diabetic macular edema (DME) and wet age-related macular degeneration. The TxGNN model predicts it may also be effective for Severe Nonproliferative Diabetic Retinopathy, with 6 clinical trials and 20 publications currently supporting this direction.

Quick Overview

Item	Content
Original Indication	Neovascular (wet) age-related macular degeneration / diabetic macular edema — Ranibizumab's globally established anti-VEGF ophthalmic indications (not documented in this evidence pack's local license data)
Predicted New Indication	Severe Nonproliferative Diabetic Retinopathy
TxGNN Prediction Score	99.99%
Evidence Level	L1
Norway Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this evidence pack. Based on known information, Ranibizumab is a humanized anti-VEGF-A Fab fragment, part of the anti-VEGF ophthalmic therapeutic class, and its efficacy in neovascular retinal diseases (including diabetic macular edema) has been proven; mechanistically, it may also be applicable to severe nonproliferative diabetic retinopathy (NPDR).

VEGF is a central driver of vascular leakage and neovascularization in diabetic retinopathy. Ranibizumab directly blocks this pathway by binding VEGF-A. Diabetic macular edema (an already-established anti-VEGF indication) and severe NPDR are both stages along the same diabetic retinal disease continuum, meaning this prediction represents an extension of an already-validated mechanism-disease relationship rather than a novel, unrelated application.

This is supported by multiple large completed Phase 3 RCTs (e.g., the DRCR.net Protocol I program, RIDE/RISE, and the Pavilion trial evaluating a Port Delivery System with ranibizumab specifically in NPDR without center-involved DME), which collectively show that anti-VEGF therapy can delay or reverse progression along the DR severity scale — reinforcing that this is a mechanistically coherent, evidence-backed extension rather than a purely model-driven prediction.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00444600	Phase 3	Completed	691	Compared laser alone, laser+triamcinolone, laser+ranibizumab, and ranibizumab alone for diabetic macular edema
NCT04503551	Phase 3	Completed	174	Port Delivery System with ranibizumab vs comparator arm in diabetic retinopathy without center-involved DME — efficacy, safety, PK
NCT02634333	Phase 3	Completed	399	Intravitreal anti-VEGF for prevention of vision-threatening complications in high-risk diabetic retinopathy eyes
NCT02834663	Phase 4	Completed	25	Intravitreal ranibizumab in NPDR with macular edema — effects on microaneurysm turnover and non-perfused retinal area
NCT03452657	Phase 3	Unknown	118	Ranibizumab vs sham injections for prevention of progression in high-risk diabetic retinopathy
NCT05222633	N/A	Unknown	1000	Real-world observational study of anti-VEGF therapy (ranibizumab, aflibercept, conbercept) in exudative AMD, proliferative DR, macular edema, and CNV

Literature Evidence

PMID	Year	Type	Journal	Key Findings
40048178	2025	RCT	JAMA Ophthalmology	Pavilion trial: Port Delivery System with ranibizumab vs monitoring in NPDR without macular edema
39673354	2024	Systematic Review	Health Technology Assessment	Anti-VEGF drugs vs laser photocoagulation for diabetic retinopathy — systematic review and meta-analysis
40347224	2025	Systematic Review	Health Technology Assessment	Anti-VEGF vs laser photocoagulation for diabetic retinopathy — systematic review and economic analysis
32606578	2020	Post-hoc RCT Analysis	Clinical Ophthalmology	Predictors of early DR regression with ranibizumab in the RIDE/RISE trials
36774994	2023	Meta-Analysis	Ophthalmology Retina	Baseline DR severity and time to DME resolution with ranibizumab — Phase 3 meta-analysis
36161830	2022	Post-hoc RCT Analysis	BMJ Open Ophthalmology	Effect of less aggressive ranibizumab treatment on Diabetic Retinopathy Severity Scale scores — RIDE/RISE open-label extension
35417296	2022	Post-hoc RCT Analysis	Ophthalmic Surgery, Lasers & Imaging Retina	Course of DR in untreated fellow eyes in RIDE and RISE
30973596	2019	Cohort	JAMA Ophthalmology	Retinal nonperfusion characteristics in severe NPDR and PDR on ultra-widefield angiography
37278412	2023	Modeling/Simulation	BMJ Open Ophthalmology	Simulation of long-term impact of intravitreal anti-VEGF therapy in severe NPDR
33966556	2021	Review	Expert Opinion on Biological Therapy	Overview of ranibizumab for the treatment of diabetic retinopathy

Norway Market Information

Ranibizumab currently holds no marketing authorization record in this evidence pack (Market status: Not Marketed, Total authorizations: 0). No product-level licensing information is available for review.

Safety Considerations

Please refer to the package insert for safety information.

(Note: key warnings, contraindications, and DDI data are flagged as a blocking data gap [DG001] in the evidence pack and require retrieval from the local regulatory authority's approved product label before proceeding to safety review.)

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Evidence level L1 is supported by multiple completed Phase 3 RCTs (DRCR.net Protocol I, RIDE/RISE, the Pavilion PDS trial) demonstrating anti-VEGF efficacy across the diabetic retinopathy severity spectrum, and the mechanistic rationale is strong since DME is already an established ranibizumab indication. However, the drug is not currently marketed in this jurisdiction, and safety/regulatory documentation is incomplete.

To proceed, the following is needed:

Local product label (warnings, contraindications, DDI) — currently a blocking data gap (DG001)
Detailed mechanism of action documentation from DrugBank (DG002)
Local market entry / registration status assessment, since the drug is currently not marketed in this jurisdiction
Confirmation of outcome for the still-"Unknown" status trial (NCT03452657) before finalizing the evidence base
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.